David A. Siegel Immunic, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Immunic, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 51,718 shares of IMUX stock, worth $54,821. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,718
Previous 47,718
8.38%
Holding current value
$54,821
Previous $52,000
63.46%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding IMUX
# of Institutions
70Shares Held
56.2MCall Options Held
100Put Options Held
350K-
Bvf Inc San Francisco, CA8.9MShares$9.44 Million0.47% of portfolio
-
Avidity Partners Management LP Dallas, TX8.27MShares$8.76 Million0.84% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$7.73 Million1.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$5.93 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X05.1MShares$5.41 Million0.0% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $32.4M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...